In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Buzz at JP Morgan--Biopharma: New Models Wanted

Executive Summary

Perhaps the loudest message from the biopharmaceutical side of the JP Morgan conference was: "Change the Big Pharma model." The theme was pervasive-in discussions of the most interesting products; among the biotechs; indeed in the Big Pharma presentations themselves.
Advertisement

Related Content

Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
At JPMorgan XXIV: Mostly Pharma but Little Strategic Agreement
Reviewing 2005: The Top Biopharma Stories
Theravance: Having Cake and Eating It
Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A
Which Segment Did You Bet On?
Why Early-Stage Dealmaking is Hot
As Specialty Pharmacy Evolves, Biotech Companies Stay Tuned
As Specialty Pharmacy Evolves, Biotech Companies Stay Tuned
Large Molecules: Too Late For Big Pharma?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel